1O CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites

Clinical research indicated that some platinum-resistant ovarian cancer patients are sensitive to Poly (ADP-ribose) polymerase inhibitors(PARPi) and it is associated with high Poly(ADP-ribosyl)lation (PARylation) activity of PARP1. However, the specific mechanism remains unclear.